Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) has earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $26.71.
CORT has been the topic of several research reports. StockNews.com initiated coverage on Corcept Therapeutics in a research report on Thursday, May 18th. They issued a “buy” rating on the stock. Truist Financial decreased their target price on Corcept Therapeutics from $28.00 to $26.00 in a research report on Friday. Jefferies Financial Group downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $35.00 to $22.00 in a research report on Wednesday, February 15th. SVB Securities started coverage on Corcept Therapeutics in a research report on Tuesday, April 11th. They issued a “market perform” rating and a $25.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Corcept Therapeutics in a research report on Wednesday, March 1st.
Insider Buying and Selling
In related news, insider Gary Charles Robb sold 30,000 shares of the business’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $23.87, for a total transaction of $716,100.00. Following the completion of the transaction, the insider now directly owns 33,997 shares of the company’s stock, valued at approximately $811,508.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 19.80% of the stock is currently owned by insiders.
Institutional Trading of Corcept Therapeutics
Corcept Therapeutics Stock Down 2.2 %
Corcept Therapeutics stock opened at $23.98 on Wednesday. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of 29.24 and a beta of 0.50. Corcept Therapeutics has a 52 week low of $17.86 and a 52 week high of $30.14. The business’s 50-day moving average price is $22.78 and its 200 day moving average price is $22.63.
Corcept Therapeutics (NASDAQ:CORT – Get Rating) last issued its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.06). Corcept Therapeutics had a net margin of 22.79% and a return on equity of 19.37%. The business had revenue of $105.70 million during the quarter, compared to analyst estimates of $104.91 million. During the same period in the previous year, the business posted $0.20 earnings per share. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. Equities analysts expect that Corcept Therapeutics will post 0.66 EPS for the current year.
Corcept Therapeutics Company Profile
Corcept Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol.
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.